Vitamin C deficiency weakens collagen in capillary and vascular walls, so severe scurvy can present with ocular hemorrhages in the conjunctiva and retina that threaten vision if not treated. Case reports and small series describe retinal hemorrhages, flame‑shaped hemorrhages, and even retrobulbar bleeding compressing the optic nerve, which can lead to optic neuropathy and visual loss in advanced cases. The encouraging point is that, when vitamin C deficiency is recognized early and promptly repleted, many ocular hemorrhages and visual symptoms can partially or fully resolve, making it critical to consider vitamin C status in patients with otherwise unexplained ocular bleeding and visual complaints. This medication is commonly used for Stomach Acid.
Errera MH, Dupas B, Man H, Gualino V, Gaudric A, Massin P. Une cause inhabituelle d'anomalies rétiniennes, hémorragies rétiniennes révélatrices de scorbut [Unusual retinal abnormality: retinal hemorrhages related to scurvy]. J Fr Ophtalmol. 2011 Mar;34(3):186.e1-3. Masuda Y, Saigusa K, Norisue Y. A Case of Scurvy Associated With Intracerebral Hemorrhage in a Patient With Alcohol Use Disorder. Cureus. 2024 Feb 23;16(2):e54777. Andrew Go Lee, et al. Ocular Manifestations of Vitamin C Deficiency. American Academy of Opthamology. November 2025. A. Martel, et al. Spontaneous eyelid and subconjunctival socket bleeding related to vitamin C deficiency: First case reportHémorragie palpébrale et sous conjonctivale spontanée sur cavité anophtalme secondaire à un déficit en vitamine C : premier cas rapporté. Journal Français d'Ophtalmologie. Volume 43, Issue 9, November 2020.
Some side effects may be linked to nutrient depletion caused by this medication.
Studies find that proton pump inhibitors (PPIs) may increase your risk of magnesium deficiency. A large study involving over 100,000 participants found a significant association between PPI use and lower magnesium levels (hypomagnesemia). PPIs work by reducing stomach acid production, which can also play a role in magnesium absorption. Individuals taking PPIs, particularly long-term use, should consider magnesium supplementation to help protect against deficiency.
Long-term use of PPIs might raise the risk of calcium deficiency and weaken bones. A potential mechanism for this is chronic hypergastrinemia, a condition where the stomach produces excess gastrin due to PPI use. This can lead to parathyroid hyperplasia, where the parathyroid glands overproduce a hormone that pulls calcium from bones. Additionally, PPIs significantly reduce stomach acid production, which can hinder calcium absorption from food in the intestines. Individuals taking PPIs, especially individuals at higher risk of bone issues or those on long-term PPI therapy, should consider calcium supplementation to help protect against deficiency.
There is evidence that proton pump inhibitors (PPIs) might decrease vitamin C levels in the body. A study showed that even a short course of omeprazole, a common PPI, reduced vitamin C levels in healthy volunteers, regardless of their dietary intake. This suggests that PPIs may reduce the bioavailability of vitamin C, meaning the body has a harder time absorbing and using it. Vitamin C plays a crucial role in immune function and antioxidant defenses and therefore individuals using PPI therapy should consider supplementation with vitamin C to protect against a deficiency.